Ranbaxy To Market Pain Killer In Canada

by Medindia Content Team on  October 6, 2006 at 6:32 PM Drug News
RSS Email Print This Page Comment
Ranbaxy To Market Pain Killer In Canada
Ranbaxy Pharmaceuticals Canada Inc. (RPCI), the wholly owned subsidiary of Indian pharma major Ranbaxy Laboratories Limited (RLL), has entered into a tie-up with Janssen-Ortho Inc. (JOI) for marketing of its generic painkiller Fentanyl in Canada.

The second product to be commercialised by RPCI, Fentanyl would be sold under Ranbaxy's label RAN under the licensing and supply agreement with Janssen-Ortho Inc, the company said in a statement Friday.

"This agreement, which also includes Risperidone, will provide Ranbaxy with an opportunity to commercialise products that continue to have a favourable impact on patient care, as well as on the Canadian healthcare system, and allow Ranbaxy to reinforce its presence in Canada," said Bill Abboud, RPCI president and general manager.

RPCI is the first India-based pharmaceutical company with a generic presence in Canada, the eighth largest pharmaceutical market in the world.

Source: IANS
SRM

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Thoracic Outlet Syndrome Top 15 Natural Painkillers 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.


Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive